Viewing Study NCT02913261

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 12:44 PM
Ignite Modification Date: 2026-01-27 @ 3:20 AM
Study NCT ID: NCT02913261
Status: COMPLETED
Last Update Posted: 2023-02-08
First Post: 2016-09-18
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Corticosteroid Refractory Acute Graft vs Host Disease View
Keywords:

Keywords

Keyword Brief Keyword Text View
None GvHD (Graft versus Host Disease) View
None INC424 View
None ruxolitinib View
None best available therapy (BAT) View
None corticosteroid-refractory acute graft vs. host disease View
None allogeneic stem cell transplantation View
None steroid refractory acute graft vs. host disease View
None Janus Kinase (JAK) inhibitor View